drugset / Trial / NCT01020305
Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer
Phase 1/2
Terminated
5 enrolled
Sandy Srinivas
American Society of Clinical Oncology · collabNational Comprehensive Cancer Network · collabWyeth is now a wholly owned subsidiary of Pfizer · collab
NaSingle-groupOpen-labelTreatment
Summary
This study evaluates if temsirolimus causes a reduction in the serum levels of prostate-specific antigen (PSA) in male subjects with castration-resistant prostate cancer (CRPC).
Timeline
- Start
- 2009-10
- Primary completion
- 2012-04
- Completion
- 2012-04
Outcome
Outcome not reported
Stopped (Enrollment): “Decision by funding sponsor due to poor accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Temsirolimus | Small molecule | 25 mg | Intravenous |
| Background | Bicalutamide | Other / unclassified | 50 mg | Oral |